Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review

Author(s): Yunhua Xu*, Yong Li, Jie Luo and Rong Tang

Volume 19, Issue 2, 2024

Published on: 16 June, 2023

Page: [309 - 312] Pages: 4

DOI: 10.2174/1574886318666230529123200

Price: $65

Abstract

Background: Osimertinib is a third-generation Tyrosine Kinase inhibitor, mainly used in non-small cell lung cancer with EGFR mutation. Its efficacy and safety have been confirmed by clinical practice. Toxic epidermolysis necrotizing disease (TEN) is a severe drug eruption that is rare in clinics and has a high mortality rate. Toxic epidermal necrotic drug rash caused by Osimeritinib is even rarer.

Objective: To investigate the rare side effects of Osimertinib through a case of toxic Epidermal necrosis.

Case Presentation: A 63-year-old female patient was diagnosed with lung adenocarcinoma with brain metastases, and genetic testing revealed an EGFR21 exon mutation. The disease progressed 24 days after the administration of gefitinib, then the patient switched to Osimertinib (80 mg QD) and, resulting in keratitis and secondary systemic toxic epidermolysis necrotizing disease (TEN). Finally, the patient died.

Conclusion: Although the clinical use of osimertinib is becoming widespread, the side effects may not be fully understood. Clinicians should pay more attention to the occurrence of the side reaction and deal with it in time.

« Previous Next »
[1]
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376(7): 629-40.
[http://dx.doi.org/10.1056/NEJMoa1612674] [PMID: 27959700]
[2]
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378(2): 113-25.
[http://dx.doi.org/10.1056/NEJMoa1713137] [PMID: 29151359]
[3]
Liu J, Li X, Shao Y, Guo X, He J. The efficacy and safety of osimertinib in treating nonsmall cell lung cancer. Medicine 2020; 99(34): e21826.
[http://dx.doi.org/10.1097/MD.0000000000021826] [PMID: 32846826]
[4]
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic: Epidermal necrolysis in United States adults. J Invest Dermatol 2016; 136(7): 1387-97.
[http://dx.doi.org/10.1016/j.jid.2016.03.023] [PMID: 27039263]
[5]
Lerch M, Mainetti C, Beretta-Piccoli BT, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necolysis. Clin Rev Allergy Immunol 2018; 54(1): 147-76.
[http://dx.doi.org/10.1007/s12016-017-8654-z] [PMID: 29188475]
[6]
Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 2018; 54(1): 147-76.
[http://dx.doi.org/10.1007/s12016-017-8654-z] [PMID: 29188475]
[7]
Nassif A, Bensussan A, Boumsell L. Toxic epidermal necrolysis: Effector cells are drug-specific cyto-toxic T cells. J Allergy Clin Immunol 2004; 114(5): 1209-15.
[http://dx.doi.org/10.1016/j.jaci.2004.07.047] [PMID: 15536433]
[8]
Wolkenstein P, Wilson YT. Toxic epidermal necrolysis: The past, the guidelines and challenges for the future. J Plast Reconstr Aesthet Surg 2016; 69(6): 733-5.
[http://dx.doi.org/10.1016/j.bjps.2016.04.016] [PMID: 27287211]
[9]
Chung W-H, Hung S-I, Hong H-S, et al. A marker for Stevens–Johnson syndrome. Nature 2004; 428(6982): 486. [J].
[http://dx.doi.org/10.1038/428486a]
[10]
Hung SI, Chung WH, Liu Z, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Phamacogenomics 2010; ll(3): 349-56.
[11]
Hung SI, Chung WH, Liou LB, et al. HLA-B*580l allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005; 102(11): 4134-9.
[http://dx.doi.org/10.1073/pnas.0409500102] [PMID: 15743917]
[12]
Enk AH, Hadaschik EN, Eming R, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Eur Acad Dermatol Venereol 2016; 30(10): 1657-69.
[http://dx.doi.org/10.1111/jdv.13725] [PMID: 27406069]
[13]
Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5(1): 39.
[http://dx.doi.org/10.1186/1750-1172-5-39] [PMID: 21162721]
[14]
Wang J, Cheng X, Lu Y, Zhou B. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des Devel Ther 2018; 12: 2163-7.
[http://dx.doi.org/10.2147/DDDT.S168248] [PMID: 30034220]
[15]
Sato I, Mizuno H, Kataoka N, et al. Osimertinib-associated toxic epidermal necrolysis in a lung cancer patient harboring an EGFR Mutation-A case report and a review of the literature. Medicina 2020; 56(8): 403.
[http://dx.doi.org/10.3390/medicina56080403] [PMID: 32796633]
[16]
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88(1): 60-8.
[http://dx.doi.org/10.1038/clpt.2009.252] [PMID: 20375998]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy